Overview

A Study of VEGF-Antisense Oligonucleotide in Combination With Pemetrexed and Cisplatin for the Treatment of Advanced Malignant Mesothelioma

Status:
Withdrawn

Trial end date:
2011-04-01

Target enrollment:

Participant gender:

Summary

This will be a single institution non-randomized phase I/II trial for patients with malignant mesothelioma stage II and above, who have not received prior chemotherapy for their disease. The purpose of this phase is to select a dose of VEGF-AS (antiangiogenesis drug)to be given with standard doses of pemetrexed followed by cisplatin on day 1 of a 21-day cycle.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

University of Southern California

Collaborator:

Sponsor Name Pending

Treatments:

Cisplatin
Pemetrexed